EU/3/13/1208: Orphan designation for the treatment of Stargardt's disease
Soraprazan
Table of contents
Overview
On 13 November 2013, orphan designation (EU/3/13/1208) was granted by the European Commission to Katairo GmbH, Germany, for soraprazan for the treatment of Stargardt's disease.
Key facts
Active substance |
Soraprazan
|
Intended use |
Treatment of Stargardt's disease
|
Orphan designation status |
Positive
|
EU designation number |
EU/3/13/1208
|
Date of designation |
13/11/2013
|
Sponsor |
Katairo GmbH
Lederstrasse 21 72127 Kusterdingen Germany Tel. +49 7071 5496184 Fax +49 7071 5496183 E-mail: info@katairo.com |
Review of designation
The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.
Patients' organisations
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
EU register of orphan medicines
The list of medicines that have received an orphan designation in the EU is available on the European Commission's website: